- recruiting
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
This study looks at how a weekly injection called semaglutide helps teenagers aged 12 to 21 with a specific type of genetic obesity. Researchers will see how it affects their weight, hunger, mood, and overall well-being over 68 weeks.
France · Germany · Netherlands - authorisedTherapeutic confirmatory (Phase III)
An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene
This study is looking at a new medicine called mibavademab for people with a specific type of genetic obesity. It aims to see how well the medicine helps reduce body weight and improve other related health measures over time.
Germany